Drug
18-FDG PET/CT
18-FDG PET/CT is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_2
2
67%
Ph not_applicable
1
33%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (66.7%)
N/A1 (33.3%)
Trials by Status
recruiting133%
completed267%
Recent Activity
1 active trials
Showing 3 of 3
completedphase_2
Imaging in MGUS, SMM and MM
NCT01237054
recruitingnot_applicable
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
NCT06537960
completedphase_2
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
NCT02814968
Clinical Trials (3)
Showing 3 of 3 trials
NCT01237054Phase 2
Imaging in MGUS, SMM and MM
NCT06537960Not Applicable
Interest of Late Images for the Assessment of Extensions in 18FGD PET-CT of Muscle-Invasive Bladder Cancers
NCT02814968Phase 2
PET/CT and WB MRI for Staging and Response in CRPC Patients Receiving Enzalutamide
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3